Payment overview · 2025
General Payments
$137.23
8 reported records · 5 companies
Healthcare provider profile · identity verified
Michelle Reisner, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JERSEY CITY, NJ · NPI 1942267158
Verified facts
What the public records show
CMS Open Payments records show Michelle Reisner, MD received $137.23 in general payments during 2025 across 8 reported records.
Novo Nordisk Inc accounted for 38.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Biktarvy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.16 | 38.7% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $36.19 | 26.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.91 | 13.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $15.00 | 10.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $13.97 | 10.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $137.23 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $53.16 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $36.19 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
84 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 726 | 204 |
| Amlodipine Besylate | Amlodipine Besylate | 544 | 152 |
| Losartan Potassium | Losartan Potassium | 434 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 372 | 92 |
| Eliquis | Apixaban | 318 | 67 |
| Simvastatin | Simvastatin | 312 | 85 |
| Metoprolol Tartrate | Metoprolol Tartrate | 299 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 299 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 281 | 84 |
| Metformin Hcl | Metformin Hcl | 272 | 82 |
| Gabapentin | Gabapentin | 244 | 62 |
| Furosemide | Furosemide | 241 | 68 |
| Lisinopril | Lisinopril | 210 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 207 | 53 |
| Alprazolam | Alprazolam | 199 | 49 |
| Valsartan | Valsartan | 194 | 51 |
| Famotidine | Famotidine | 193 | 61 |
| Carvedilol | Carvedilol | 192 | 53 |
| Jardiance | Empagliflozin | 189 | 35 |
| Mirtazapine | Mirtazapine | 186 | 58 |
| Omeprazole | Omeprazole | 180 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 51 |
| Nifedipine Er | Nifedipine | 162 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 142 | 35 |
| Azithromycin | Azithromycin | 139 | 100 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 44 |
| Montelukast Sodium | Montelukast Sodium | 134 | 31 |
| Tramadol Hcl | Tramadol Hcl | 117 | 28 |
| Donepezil Hcl | Donepezil Hcl | 108 | 32 |
| Allopurinol | Allopurinol | 105 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 104 | 17 |
| Mounjaro | Tirzepatide | 103 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 34 |
| Levetiracetam | Levetiracetam | 92 | 26 |
| Januvia | Sitagliptin Phosphate | 90 | 21 |
| Sertraline Hcl | Sertraline Hcl | 87 | 21 |
| Farxiga | Dapagliflozin Propanediol | 84 | 20 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 83 | 18 |
| Potassium Chloride | Potassium Chloride | 79 | 20 |
| Trazodone Hcl | Trazodone Hcl | 79 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 27 |
| Lorazepam | Lorazepam | 67 | 32 |
| Spironolactone | Spironolactone | 64 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 16 |
| Glimepiride | Glimepiride | 58 | 22 |
| Irbesartan | Irbesartan | 57 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 16 |
| Enalapril Maleate | Enalapril Maleate | 51 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 35 |
| Naproxen | Naproxen | 49 | 31 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 49 | 18 |
| Humalog Kwikpen U-100 | Insulin Lispro | 47 | 12 |
| Ramipril | Ramipril | 47 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 34 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | 16 |
| Fluocinonide | Fluocinonide | 45 | 22 |
| Memantine Hcl | Memantine Hcl | 45 | 20 |
| Nystatin | Nystatin | 45 | 20 |
| Solifenacin Succinate | Solifenacin Succinate | 45 | 22 |
| Ammonium Lactate | Ammonium Lactate | 43 | 14 |
| Lactulose | Lactulose | 42 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 16 |
| Trulicity | Dulaglutide | 41 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | 14 |
| Clotrimazole | Clotrimazole | 39 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 13 |
| Finasteride | Finasteride | 37 | 16 |
| Meloxicam | Meloxicam | 37 | 19 |
| Mupirocin | Mupirocin | 37 | 13 |
| Topiramate | Topiramate | 37 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 36 | suppressed |
| Clonazepam | Clonazepam | 36 | 13 |
| Clonidine | Clonidine | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Methimazole | Methimazole | 33 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 33 | 16 |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 31 | suppressed |
| Prednisone | Prednisone | 31 | 15 |
| Torsemide | Torsemide | 31 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 30 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 30 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 25 |
| Ozempic | Semaglutide | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 15 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | 13 |
| Ibuprofen | Ibuprofen | 28 | 15 |
| Latanoprost | Latanoprost | 28 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 26 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 11 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Nyamyc | Nystatin | 24 | 11 |
| Ofloxacin | Ofloxacin | 24 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 23 | 12 |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | 12 |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Alogliptin | Alogliptin Benzoate | 20 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Enulose | Lactulose | 18 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Lorazepam Intensol | Lorazepam | 14 | 11 |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Cymbalta | Duloxetine Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $137.23 · 8 records | Novo Nordisk Inc | Dexcom G6 Transmitter, Korlym, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error